This was also demonstrated in another clinical analysis of sarcomas, where the killing of tumor cells by CD8+ T cells was often blocked by immune checkpoints on the tumor, such as PD-L1 and CTLA-4, and in recent years there has been a flurry of activity regarding ICB therapies (46, 47). The gene discussed is CD8A; the disease is neoplasm.